Cite
Golestani M, Eshghi P, Rasekh HR, et al. Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran. Iran J Pharm Res. 2016;15(2):669-77
Golestani, M., Eshghi, P., Rasekh, H. R., Cheraghali, A. M., Salamzadeh, J., Naderi, M., Managhchi, M. R., Hoorfar, H., Toogeh, G. R., Imani, A., Khodayari, M. T., Habibpanah, B., & Hantooshzadeh, R. (2016). Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran. Iranian journal of pharmaceutical research : IJPR, 15(2), 669-77.
Golestani, Mina, et al. "Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran." Iranian journal of pharmaceutical research : IJPR vol. 15,2 (2016): 669-77.
Golestani M, Eshghi P, Rasekh HR, Cheraghali AM, Salamzadeh J, Naderi M, Managhchi MR, Hoorfar H, Toogeh GR, Imani A, Khodayari MT, Habibpanah B, Hantooshzadeh R. Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran. Iran J Pharm Res. 2016;15(2):669-77. PMID: 27642341; PMCID: PMC5018298.
Copy
Download .nbib